Can a simple blood test predict leukemia risk after cancer therapy?

NCT ID NCT07675967

First seen Jun 30, 2026 · Last updated Jul 01, 2026 · Updated 1 time

Summary

This study investigates clonal hematopoiesis (CH) — small mutations in blood cells that can arise naturally or after cancer treatment — in adults receiving chemotherapy or radiation for solid tumors like breast, lung, or colorectal cancer. Researchers will collect blood, saliva, urine, stool, and tissue samples from 5,000 participants before and during therapy to track how CH changes over time. The goal is to build a tool that predicts who is at highest risk for developing therapy-related myeloid neoplasms (t-MNs), a serious blood cancer, and ultimately find ways to prevent it.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

What this could lead to
If successful, this research could lead to a risk prediction algorithm that identifies patients most likely to develop therapy-related leukemia, potentially guiding preventive strategies.
What could go wrong
This is an observational study, not a treatment trial. It may not directly change patient care, and the findings might not apply to all cancer types or treatments.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for BREAST CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Study contacts

  • Contact

    Email: •••••@•••••

Locations

  • Dana-Farber Cancer Institute

    RECRUITING

    Boston, Massachusetts, 02115, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.